ライフサイエンスコーパス: ibritumomab

1 ve study of 28 NHL patients treated with 90Y-ibritumomab.

2 uximab 250 mg/m(2) days -7 and 0, then (90)Y-ibritumomab 14.8 MBq/kg day 0; maximum 1,184 MBq) or no

3 ost-rituximab treatment imaging with (111)In-ibritumomab and blood pharmacokinetics.

4 tic leukemia was 0.50% versus 0.07% in (90)Y-ibritumomab and control groups, respectively (P = .042).

5 -CD20 murine IgG1 kappa monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan,

6 (90)Y-ibritumomab consolidation after achieving PR or CR/CRu t

7 on treatment were randomly assigned to (90)Y-ibritumomab consolidation therapy (rituximab 250 mg/m(2)

8 For (90)Y-ibritumomab consolidation, median PFS was 4.1 years (v 1

9 Changes in (90)Y-ibritumomab dosimetry after 4 wk of rituximab treatment

10 e assessment of impact of rituximab on (90)Y-ibritumomab dosimetry.

11 ntional doses of (131)I-tositumomab or (90)Y-ibritumomab eventually relapse.

12 111In-ibritumomab findings were positive in 19 patients and ne

13 ent was seen in patients with negative 111In-ibritumomab findings, whereas a higher rate of disease p

14 py was noted in patients with positive 111In-ibritumomab findings.

15 2) dose of rituximab plus 185 MBq of (111)In-ibritumomab for a second dosimetry evaluation.

16 mg/m(2) of rituximab plus 185 MBq of (111)In-ibritumomab for initial dosimetry evaluation.

17 ations from our clinical experience with 90Y-ibritumomab in the management of NHL.

18 90Y-ibritumomab induced objective responses in 22 of 28 pati

19 amera images were acquired after the (111)In-ibritumomab injection.

20 90Y-ibritumomab is an antibody targeting CD20 receptors on t

21 mine whether the therapeutic effect of (90)Y-ibritumomab might be enhanced by a full course of rituxi

22 r 409 patients available for analysis ((90)Y-ibritumomab, n = 207; control, n = 202), estimated 8-yea

23 THODS Blood samples from 414 patients ((90)Y-ibritumomab, n = 208; control, n = 206) were evaluated u

24 The doses of 90Y-ibritumomab ranged from 629 to 1,258 MBq (17-34 mCi).

25 were compared with the findings of the 111In-ibritumomab scans.

26 f rituximab followed by single dose of (90)Y-ibritumomab, the trial included pre- and post-rituximab

27 efficacy and toxicity of fractionated (90)Y-ibritumomab tiuxetan ((90)Y-IT) as initial therapy of fo

28 later with rituximab (250 mg/m(2)) and (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]).

29 ioimmunotherapy with a reduced dose of (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]; maximum 32

30 ubsequently performed a trial in which (90)Y-ibritumomab tiuxetan (0.4 mCi/kg) was added to the fluda

31 te peripheral blood B cells, then yttrium-90 ibritumomab tiuxetan (0.4 mCi/kg; maximum, 32 mCi) intra

32 odgkin's lymphoma received standard-dose 90Y ibritumomab tiuxetan (14.8 MBq/kg [0.4 mCi/kg]) followed

33 to treat was made after imaging with (111)In-ibritumomab tiuxetan (4.0% of all cases captured); 16 of

34 ximab (250 mg/m(2)) and injection of (111)In ibritumomab tiuxetan (5 mCi [185 MBq]) for dosimetry eva

35 An imaging/dosimetry dose of indium-111 ibritumomab tiuxetan (5 mCi) was injected after rituxima

36 Yttrium-90 ibritumomab tiuxetan (IDEC-Y2B8) is a murine immunoglobu

37 ents received 131I-tositumomab (n=23) or 90Y-ibritumomab tiuxetan (n=10) and underwent 18F-FDG PET/CT

38 Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) and tositumomab-131I (Bex

39 eviously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT)

40 Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceutical, San

41 ion on five separate protocols that used 90Y ibritumomab tiuxetan 0.4 mCi/kg.

42 ted that when measuring all volumes of (90)Y-ibritumomab tiuxetan activity prescriptions, only a sing

43 = 150,000 cells/mm(3) for the standard (90)Y-ibritumomab tiuxetan administered dose (15 MBq/kg [0.4 m

44 = 100,000 cells/mm(3) for the reduced (90)Y-ibritumomab tiuxetan administered dose (7.4-11 MBq/kg [0

45 Both ibritumomab tiuxetan administered doses were preceded by

46 on absorbed doses for (111)In- and for (90)Y-ibritumomab tiuxetan administered to 10 cancer patients

47 atients and their family members after (90)Y-ibritumomab tiuxetan administration.

48 pproximately 400) was not treated with (90)Y-ibritumomab tiuxetan after imaging with (111)In-ibritumo

49 single-center clinical experience with (90)Y-ibritumomab tiuxetan and (131)I-tositumomab for therapy

50 d not significantly differ between the (90)Y-ibritumomab tiuxetan and (131)I-tositumomab groups.

51 (mean +/- SD, 3.418 +/- 1.49) and that (90)Y-ibritumomab tiuxetan and (131)I-tositumomab were expensi

52 Both (90)Y-ibritumomab tiuxetan and (131)I-tositumomab were well to

53 n 57% and 56% of patients treated with (90)Y-ibritumomab tiuxetan and (131)I-tositumomab, respectivel

54 reports of the efficacy and safety of (90)Y-ibritumomab tiuxetan and (131)I-tositumomab, these thera

55 both 14-27 days before treatment with (90)Y-ibritumomab tiuxetan and 4-6 months after treatment.

56 enters, were administered the tracer (111)In-ibritumomab tiuxetan and assessed using planar scintilla

57 dministration approval for marketing - Y(90) ibritumomab tiuxetan and I(131) tositumomab, given as th

58 The single-agent activity of (90)Y-ibritumomab tiuxetan and its favorable safety profile wa

59 e declines in platelet counts than did (90)Y-ibritumomab tiuxetan and may be a more appropriate choic

60 nse (CR) rates were 30% and 16% in the (90)Y ibritumomab tiuxetan and rituximab groups, respectively

61 ared with previously published dosimetry for ibritumomab tiuxetan and the product package insert.

62 (90)Y- and (131)I-anti-CD20 antibodies (ibritumomab tiuxetan and tositumomab, respectively) have

63 d more frequently after treatment with (90)Y-ibritumomab tiuxetan and was associated with prolongatio

64 d and Drug Administration has approved (90)Y-ibritumomab tiuxetan anti-B-cell NHL mAb as the first co

65 (111)In- and (90)Y-ibritumomab tiuxetan are labeled at commercial radiophar

66 tic regimen in patients treated with (111)In-ibritumomab tiuxetan between March 27, 2002, and March 3

67 imab to clear peripheral B-cells and improve ibritumomab tiuxetan biodistribution.

68 We conclude that high-dose 90Y-ibritumomab tiuxetan can be combined safely with high-do

69 CHOP given for four cycles followed by (90)Y-ibritumomab tiuxetan compared favorably with historical

70 (90)Y-ibritumomab tiuxetan consists of a murine monoclonal ant

71 with 3 cycles of CHOP plus IFRT followed by ibritumomab tiuxetan consolidation had outcomes that com

72 313 trial, we evaluated the impact of adding ibritumomab tiuxetan consolidation to 3 cycles of standa

73 The median 90Y-ibritumomab tiuxetan dose was 71.6 mCi (2649.2 MBq; rang

74 simetry (day -21) with 5 mCi (185 MBq) 111In-ibritumomab tiuxetan following 250 mg/m2 rituximab, foll

75 e biodistribution and one dose of indium-111 ibritumomab tiuxetan for imaging and dosimetry.

76 he safety and efficacy of yttrium-90 ((90)Y) ibritumomab tiuxetan given as consolidation of complete

77 rophil count nadir was shorter for the (90)Y-ibritumomab tiuxetan group than for the (131)I-tositumom

78 radioimmunotherapy was greater in the (90)Y-ibritumomab tiuxetan group than in the (131)I-tositumoma

79 ion of response was 14.2 months in the (90)Y ibritumomab tiuxetan group versus 12.1 months in the con

80 ORR was 80% for the (90)Y ibritumomab tiuxetan group versus 56% for the rituximab

81 The predominant toxicity of 90Y ibritumomab tiuxetan has been myelosuppression, and conc

82 t-Line Indolent Trial of yttrium-90 ((90)Y) -ibritumomab tiuxetan in advanced-stage follicular lympho

83 conducted a phase 1/2 trial of high-dose 90Y-ibritumomab tiuxetan in combination with high-dose etopo

84 r (131)I-tositumomab and the liver for (90)Y-ibritumomab tiuxetan in myeloablative NHL treatment regi

85 he safety and efficacy of yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients with relapsed or refrac

86 This study evaluated ibritumomab tiuxetan in the treatment of rituximab-refra

87 In summary, (90)Y-ibritumomab tiuxetan introduces (90)Y into clinical prac

88 90Y-ibritumomab tiuxetan is a novel radioimmunotherapeutic a

89 Ibritumomab tiuxetan is an anti-CD20 murine IgG1 kappa m

90 (90)Y-ibritumomab tiuxetan is dosed on the basis of the patien

91 transplantation after prior therapy with 90Y ibritumomab tiuxetan is feasible and reasonably well tol

92 emissions associated with the therapy, (90)Y-ibritumomab tiuxetan is routinely administered on an out

93 Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has

94 Radioimmunotherapy with (90)Y ibritumomab tiuxetan is well tolerated and produces stat

95 Dose-escalated (90)Y ibritumomab tiuxetan may be safely combined with high-do

96 ioimmunotherapy with 131I-tositumomab or 90Y-ibritumomab tiuxetan not only induces high response rate

97 administered dose of 185 MBq (5 mCi) (111)In-ibritumomab tiuxetan on day 0, evaluated with dosimetry,

98 dose of 7.4-15 MBq/kg (0.2-0.4 mCi/kg) (90)Y-ibritumomab tiuxetan on day 7.

99 roved anti-CD20 radioimmunoconjugates ((90)Y-ibritumomab tiuxetan or (131)I-tositumomab) have had enc

100 Ibritumomab tiuxetan produces durable responses in patie

101 Ibritumomab tiuxetan radioimmunotherapy is effective in

102 Ibritumomab tiuxetan radioimmunotherapy targets the same

103 genous leukemia (t-AML) after treatment with ibritumomab tiuxetan radioimmunotherapy.

104 on-Hodgkin's lymphoma (NHL) treated with the ibritumomab tiuxetan regimen in registration and compass

105 The ibritumomab tiuxetan regimen included an infusion of rit

106 An ibritumomab tiuxetan regimen was initiated 3 to 6 weeks

107 ear to be increased after treatment with the ibritumomab tiuxetan regimen.

108 alone, at which one may underestimate (90)Y-ibritumomab tiuxetan response by considering inactive re

109 kinetic data from 4 clinical trials of (90)Y-ibritumomab tiuxetan RIT for relapsed or refractory B-ce

110 Single-dose (90)Y ibritumomab tiuxetan RIT has an acceptable safety profil

111 ment by NHL can be treated safely with (90)Y-ibritumomab tiuxetan RIT on the basis of a fixed, weight

112 use of a procedure for radiolabeling (111)In-ibritumomab tiuxetan that differed from that in the pres

113 The ibritumomab tiuxetan therapeutic regimen consists of a d

114 s to verify completion of treatment with the ibritumomab tiuxetan therapeutic regimen in patients tre

115 of an estimated 1,144-1,192 patients in whom ibritumomab tiuxetan therapy was initiated (case capture

116 antation with stem cells collected after 90Y ibritumomab tiuxetan therapy.

117 g/m2 rituximab, followed a week later by 90Y-ibritumomab tiuxetan to deliver a target dose of 1000 cG

118 Adding 90Y ibritumomab tiuxetan to high-dose BEAM with autologous s

119 The addition of (9)(0)Y-ibritumomab tiuxetan to NMAT is safe and yields early re

120 ad experienced disease progression after 90Y ibritumomab tiuxetan treatment and received subsequent t

121 The ibritumomab tiuxetan treatment regimen consisted of pret

122 ble superior assessment of response to (90)Y-ibritumomab tiuxetan treatment than the use of CT alone,

123 131I-tositumomab and those who received 90Y-ibritumomab tiuxetan was demonstrated (-31%+/-51% vs. -4

124 The therapeutic dose of (90)Y ibritumomab tiuxetan was followed by high-dose BEAM and

125 novel radioimmunotherapy yttrium-90 ((90)Y) ibritumomab tiuxetan with a control immunotherapy, ritux

126 y and efficacy of combining yttrium-90 (90Y) ibritumomab tiuxetan with high-dose carmustine, cytarabi

127 Of the responders, 29.5% used only (90)Y-ibritumomab tiuxetan, 7.6% used only (131)I-tositumomab,

128 With the approval of (90)Y-ibritumomab tiuxetan, and based on the results of numero

129 itumomab tiuxetan after imaging with (111)In-ibritumomab tiuxetan, because of altered biodistribution

130 ived 0.4 mCi/kg (maximum, 32 mCi/kg) (9)(0)Y-ibritumomab tiuxetan, fludarabine, and 2 Gy total body i

131 rituximab, 250 mg/m(2), followed by (111)In-ibritumomab tiuxetan, for imaging, on day 1 and a dose o

132 1 and a dose of rituximab followed by (90)Y-ibritumomab tiuxetan, for therapy, on day 7, 8, or 9.

133 Yttrium Y 90 ibritumomab tiuxetan, recently approved by the Food and

134 compared to patients who did not receive 90Y ibritumomab tiuxetan, there was no significant differenc

135 ies, (131)iodine-tositumomab and (90)yttrium-ibritumomab tiuxetan, were FDA-approved more than a deca

136 icroL received a dose of 0.4 mCi/kg of (90)Y-ibritumomab tiuxetan, whereas those with a platelet coun

137 d at 2-24 h and at 48-72 h after the (111)In-ibritumomab tiuxetan, with an optional third scan at 90-

138 We hypothesized that (9)(0)Y-ibritumomab tiuxetan-based NMAT would facilitate early c

139 the beta-emitting radiopharmaceutical (90)Y-ibritumomab tiuxetan.

140 e studies of outpatient treatment with (90)Y ibritumomab tiuxetan.

141 at of control groups who did not receive 90Y ibritumomab tiuxetan.

142 apy given to patients who relapsed after 90Y ibritumomab tiuxetan.

143 on was the primary toxicity noted with (90)Y ibritumomab tiuxetan.

144 lar to that in patients not treated with 90Y ibritumomab tiuxetan.

145 patients using (131)I-tositumomab and (90)Y-ibritumomab tiuxetan.

146 tients (50 eligible patients) received (90)Y-ibritumomab tiuxetan.

147 ovel conditioning regimen combining NMA with ibritumomab tiuxetan.

148 ntravenously administered (111)In- and (90)Y-ibritumomab tiuxetan.

149 Abs) (131)iodine-tositumomab and (90)yttrium-ibritumomab tiuxetan.

150 /- 1.64 GBq (range, 0.42-7.54 GBq) for (90)Y-ibritumomab tiuxetan.

151 weight-based dosing regimen used with (90)Y-ibritumomab tiuxetan.

152 (2-24 h) after the administration of (111)In-ibritumomab tiuxetan.

153 t 2-24 h after the administration of (111)In-ibritumomab tiuxetan.

154 adioimmunotherapy for NHL (20 received (90)Y-ibritumomab tiuxetan; 18 received (131)I-tositumomab).

155 90 ((90)Y)-labeled anti-CD20 antibody ((90)Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corp

156 a multicenter phase II trial of (90)yttrium-ibritumomab-tiuxetan ((90)YIT) as first-line stand-alone

157 ssion (CR) before transplant by adding (90)Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen.

158 A higher rate of complete response after 90Y-ibritumomab treatment was seen in patients with negative

159 imated 8-year overall PFS was 41% with (90)Y-ibritumomab versus 22% for control (hazard ratio [HR], 0

160 ext treatment (TTNT) was 8.1 years for (90)Y-ibritumomab versus 3.0 years for control (P < .001) with

161 R/CRu after induction, 8-year PFS with (90)Y-ibritumomab was 48% versus 32% for control (HR, 0.61; P

162 A diagnostic dose of 111In-ibritumomab was administered on day 0, and imaging follo